Clinical Guest Contributors

  1. How A $96M Gift Is Transforming Pediatric Brain Cancer Clinical Trial Infrastructure 9/1/2026

    By pairing donor priorities with research needs at Children's National, Milken Institute SPARC is turning philanthropy into faster trials, stronger infrastructure, and long-term care goals.

  2. Lessons In Forecasting Discipline From A $40B Supply Chain 8/31/2026

    Forecasting errors rarely start with the algorithm. They start when protocol changes, enrollment and site data reach the supply plan too late to prevent waste and disruption.

  3. The Pharmacy Benefit No One Is Managing: Clinical Research As A Care Option 8/28/2026

    Pharmacies could make trials more accessible — if they preserve patient trust while research partners handle the operational burden.

  4. Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections 8/27/2026

    Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.

  5. Planning A Global Clinical Trial With The Right Sites, Not The Most Sites 8/27/2026

    Less is more for Yi Larson and the team at Excursion Therapeutics, which opted to build right site network — not the largest one — for its Phase 2 trial.

  6. Turning A Historically Limited Modality Into A Respiratory Drug Opportunity 8/26/2026

    How can sponsors revive a promising modality with known safety limits? Vast Therapeutics CEO Nate Stasko, Ph.D., explains how ALX1 is reshaping nitric oxide delivery.

  7. It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials 8/26/2026

    Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?

  8. Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy 8/25/2026

    Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.

  9. What BriaCell's Trial Design Says About Real-World Cancer Research 8/24/2026

    BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.

  10. Accountability Gaps Can Break Clinical Supply Contracts 8/24/2026

    Contract gaps can create clinical supply failures when responsibilities differ across agreements. See how aligning obligations can prevent costly disputes, delays, and risks.